McKesson Q4 revs $90.8B (+19%), adj. EPS $10.12 (+64%); guides FY26 adj. EPS $36.75-37.55; plans Med-Surg spin-off

MCKESSON CORP

2025-FY EPS reported $25.72 vs consensus $9.31 ▲ beat (+176.3%)

Q4 consolidated revenues $90.8B (+19% YoY); GAAP diluted EPS $10.01; adjusted diluted EPS $10.12 (+64%).
Full-year FY25 revenues $359.1B (+16%); adjusted EPS $33.05 (+20%); cash flow from ops $6.1B, FCF $5.2B.
FY26 adjusted EPS guidance $36.75-$37.55 (11-14% growth); reaffirms long-term adj. EPS growth target 12-14%.
Announces intention to separate Medical-Surgical Solutions into independent company to unlock shareholder value.
U.S. Pharmaceutical long-term segment profit growth target raised from 5-7% to 6-8%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.